# Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma

> **NCT02248428** · PHASE3 · UNKNOWN · sponsor: **Jinling Hospital, China** · enrollment: 130 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Clarithromycin
- **DRUG:** Thalidomide
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02248428
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-04
- **Primary completion:** 2019-09
- **Final completion:** 2020-09
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2017-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02248428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02248428, "Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02248428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*